



ACR 2023: Top abstracts in Lupus

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in lupus.

Brought to you by SES



Scientific Education Support

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://lupushub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.



Click
the abstracts
to view



Systemic lupus erythematosus

0597	<u>Efficacy of anifrolumab in systemic lupus erythematosus by overall and organ-specific SLEDAI-2K improvements: Results from the randomized, placebo-controlled phase 3 long-term extension study</u>
0608	<u>Efficacy of cenerimod in patients with high IFN-1 gene expression signature and high anti-dsDNA antibody levels: Post-hoc analysis from a phase 2 study</u>
1489	<u>Treatment with upadacitinib in patients with systemic lupus erythematosus results in the inhibition of B-cell-related biomarkers: Analysis of the M19-130 (SLEek) phase 2 study</u>
2328	<u>Deucravacitinib, an oral, allosteric, tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus: Patient-reported outcomes in a phase 2 trial</u>
2487	<u>Phase 2 safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; Anti-BAFFR mAb) administered monthly over 28 Weeks in patients with systemic lupus erythematosus (SLE) of moderate-to-severe activity</u>
2488	<u>Efficacy and safety of ABBV-599 high dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: A phase 2, double-blind, placebo-controlled trial</u>
L13	<u>An open-label, multicenter, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T Cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: Preliminary results</u>

Lupus nephritis

0595	<u>Renal involvement in patients with systemic lupus erythematosus treated with anifrolumab compared with placebo over a 4-year period</u>
0782	<u>Comparison of dual-immunosuppressive therapy with a voclosporin-based, triple-immunosuppressive regimen for lupus nephritis in the ALMS and AURORA 1 studies</u>
0784	<u>Kidney-related outcomes and steroid-sparing effects in patients with active lupus nephritis treated with obinutuzumab: A post hoc analysis of a phase 2 trial</u>





Follow us on Twitter to keep
up to date with the latest
from ACR Convergence 2023

@lupus_hub

#ACR23

<https://lupushub.com>